Portal de investigación
Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Garcia-Hernandez, FJ
- Castillo-Palma, MJ
- Tolosa-Vilella, C
- Guillen-del Castillo, A
- Rubio-Rivas, M
- Freire, M
- Vargas-Hitos, JA
- Rodriguez-Carballeira, M
- Espinosa-Garriga, G
- Colunga-Arguelles, D
- Ortego-Centeno, N
- Trapiella-Martinez, L
- Rodero-Roldan, MM
- Pla-Salas, X
- Perales-Fraile, I
- del Campo, IPM
- Chamorro, AJ
- Gimenez, RAFD
- Madronero-Vuelta, AB
- Ruiz-Munoz, M
- Fonollosa-Pla, V
- Simeon-Aznar, CP
- SSSG
- Autoimmune Dis Study Grp GEAS
- Spanish Soc Internal Med SEMI
Grupos
Abstract
IntroductionOur objective was to evaluate the pulmonary hypertension (PH) data for Spanish patients with systemic sclerosis (SSc), define the PH types and determine the associated factors.MethodDescriptive study of PH-related data from the multicentre RESCLE registry. Estimated systolic pulmonary artery pressure (esPAP), measured via echocardiogram was considered elevated if 35mmHg. Left heart disease (LHD) and interstitial lung disease (ILD) were identified. When performed, data from right heart catheterisation (RHC) were collected.ResultsesPAP was elevated in 350 of 808 patients (43.3%). One hundred and forty-four patients (17.8%) were considered to have PH (88 via RHC and the rest due to elevated esPAP along with evidence of significant LHD or ILD): PAH 3.7%, secondary to ILD 8.3%, secondary to LHD 2.8% and unclassified 3%. Prevalence of elevated esPAP was greater in diffuse SSc (dSSc) than in limited scleroderma (lSSc) (50.5 vs. 42.2%, p 0.046). In the group with elevated esPAP, a lower prevalence of anti-centromere antibodies (41.9% vs. 52.3%, p 0.006) and a greater prevalence of anti-topoisomerase-1 antibodies (ATA) (25.1% vs. 18.6%, p 0.04) were observed compared to the group with normal esPAP. Patients with elevated esPAP had a lower rate of digital ulcers (50.6% vs. 60.2%, p 0.007) and esophageal involvement (83.6% vs. 88.7%, p 0.07) and higher rate of renal crisis (4.6% vs. 1.8%, p 0.066).ConclusionsPrevalence of PAH was lower than expected (3.7%). Probability of having elevated esPAP was higher among patients with dSSc and among those with ATA.
Datos de la publicación
- ISSN/ISSNe:
- 0770-3198, 1434-9949
- Tipo:
- Article
- Páginas:
- 1117-1124
- PubMed:
- 30535994
- Factor de Impacto:
- 0,755 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
CLINICAL RHEUMATOLOGY SPRINGER LONDON LTD
Citas Recibidas en Web of Science: 8
Documentos
- No hay documentos
Filiaciones
Keywords
- Anti-centromere antibodies; Pulmonary hypertension; Systemic sclerosis
Campos de Estudio
Cita
Garcia FJ,Castillo MJ,Tolosa C,Guillen A,Rubio M,Freire M,Vargas JA,TODOLI JA,Rodriguez M,Espinosa G,Colunga D,Ortego N,Trapiella L,Rodero MM,Pla X,Perales I,del Campo I,Chamorro AJ,Gimenez R,Madronero AB,Ruiz M,Fonollosa V,Simeon CP,SSSG,Autoimmune Dis Study GEAS GRP,Spanish Soc Internal Med S. Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry. Clin. Rheumatol. 2019. 38. (4):p. 1117-1124. IF:2,394. (3).